Related Experiment Video
Updated: Mar 27, 2026
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Yixiao Formula Suppresses Myocardial Fibrosis Through UpregulatingmiR-133a and Downregulating TGF-β/Smads Signal
Qiyao Zhao1,2, Yalu Wen3, Honghui Wu4
1Department of Nephrology and Endocrine (II), Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, bucm.edu.cn.
Background:
Yixiao formula (YXF), a traditional Chinese herbal medicine, has demonstrated clinical efficacy in alleviating symptoms of diabetic cardiomyopathy (DCM). The therapeutic mechanism underlying YXF's effects on DCM remains poorly understood. Myocardial fibrosis is a key pathogenic mechanism in DCM, and previous studies have indicated that miR-133a may be involved in its progression. Given that the TGF-β/Smads signaling pathway is a well-established mediator of myocardial fibrosis, investigating the mechanistic role of YXF through miR-133a and the TGF-β/Smads pathway warrants further exploration.
Objective:
The main objective of this study is to investigate the potential contribution of the TGF-β/Smads pathway to the effects of YXF, as well as the role of miR133a, through in vivo DCM models and in vitro experiments.
Materials And Methods:
Spontaneously diabetic KKAy mice were used to establish a DCM model by continuous high-fat feeding, with C57BL/6 mice as controls. Echocardiography, body weight, and blood glucose data were collected every 4 weeks to examine the effects of YXF on blood glucose levels and changes in cardiac function and structure in DCM mice. Immunohistochemistry, RT-qPCR, and western blot were used to detect the expression levels of the TGF-β/Smads pathway. Additionally, the potential molecular mechanism of YXF in mouse cardiac fibroblasts (MCFs) was investigated by knocking down miR-133a.
Results:
YXF improved fasting blood glucose levels in DCM mice, promoted cardiac diastolic function, upregulated miR133a, and inhibited the expression of the TGF-β/Smads pathway. Furthermore, when miR133a inhibitors were transfected under YXF intervention, we found that YXF's inhibitory effect on the TGF-β/Smads pathway was weakened.
Conclusion:
Through this study, we found that YXF can increase miR133a and inhibit the expression of the TGF-β/Smads pathway, thereby inhibiting myocardial fibrosis and exerting a protective effect on DCM.
